- Trials with a EudraCT protocol (27)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
27 result(s) found for: Bone mineral content.
Displaying page 1 of 2.
EudraCT Number: 2014-004104-30 | Sponsor Protocol Number: 307-MET-9002-0009 | Start Date*: 2015-04-01 |
Sponsor Name:Pharmacia & Upjohn S.A. | ||
Full Title: Treatment With Recombinant Human Growth Hormone (Genotonorm) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety | ||
Medical condition: Juvenile idiopathic arthritis (JIA) and nephrotic syndrome (NeS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2007-001716-23 | Sponsor Protocol Number: 452622 | Start Date*: 2007-12-03 | |||||||||||
Sponsor Name:Southampton University Hospitals NHS Trust | |||||||||||||
Full Title: A Double-Blind Randomised Placebo-Controlled Trial of Vitamin D Supplements for Pregnant Women with Low Levels of Vitamin D in Early Pregnancy | |||||||||||||
Medical condition: Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013777-17 | Sponsor Protocol Number: 1 | Start Date*: 2010-02-08 |
Sponsor Name:Central Manchester and Manchester University Children's Hospital NHS Trust. [...] | ||
Full Title: The effect of pamidronate treatment on bone health in patients with neuromuscular disease undergoing hip surgery. | ||
Medical condition: Children with neuromuscular conditions undergoing hip surgery. Aiming to identify whether pamidronate a licenced medicine mainatins bone mineral density in patients with neuromuscular conditions un... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-001666-40 | Sponsor Protocol Number: CZOL446H2202E1 | Start Date*: 2005-02-01 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: An international, multicenter, randomized, open-label, safety and efficacy trial of intravenous zoledronic acid administered either once or twice yearly in children with severe osteogenesis imperfe... | ||
Medical condition: Osteogenesis Imperfecta | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) GB (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019380-11 | Sponsor Protocol Number: 09/0278 | Start Date*: 2010-09-30 |
Sponsor Name: | ||
Full Title: Autologous cell therapy of fracture non-union – cell phenotype as a predictor of outcome | ||
Medical condition: delayed fracture union (fracture non-union) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004729-25 | Sponsor Protocol Number: 9741 | Start Date*: 2006-04-14 |
Sponsor Name:R & D Directorate,Central Manchester and Manchester Children's University Hospitals NHS Trust | ||
Full Title: A pilot randomised controlled trial to determine if vitamin D treatment will result in a greater bone mass acquisition in pubertal girls | ||
Medical condition: Hypovitaminosis D in healthy subjects / Subclinical vitamin D deficiency. Recently there have been many reports of vitamin D deficiency in healthy adolescents worldwide. It is not yet known wheth... | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000745-21 | Sponsor Protocol Number: P1200_12 | Start Date*: 2012-12-10 | |||||||||||
Sponsor Name:Schriners Hospitals for Children | |||||||||||||
Full Title: An international, multicenter, open-label, efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta | |||||||||||||
Medical condition: Children suffering from severe Osteogenesis Imperfecta | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000647-14 | Sponsor Protocol Number: 15782601 | Start Date*: 2016-05-23 |
Sponsor Name:University Hospital Toulouse | ||
Full Title: Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial | ||
Medical condition: Noonan syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001831-38 | Sponsor Protocol Number: ENB-009-10 | Start Date*: 2017-05-09 | |||||||||||
Sponsor Name:Alexion Pharma GmbH | |||||||||||||
Full Title: A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline... | |||||||||||||
Medical condition: Hypophosphatasia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000094-37 | Sponsor Protocol Number: FAO_06_011 | Start Date*: 2008-05-06 | |||||||||||
Sponsor Name:Glostrup University Hospital | |||||||||||||
Full Title: Effect of PTH(1-34)-treatment on fracture healing in vivo | |||||||||||||
Medical condition: pertrocanteric femur fractures or collum humerus fractures in osteoporotic postmenopausal women | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007456-34 | Sponsor Protocol Number: 3100N0-2213-WW | Start Date*: 2009-09-04 | ||||||||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc | ||||||||||||||||||
Full Title: Estudio de fase 2, multicéntrico, aleatorizado, controlado con producto activo, de grupos paralelos, búsqueda de dosis y de la seguridad de la proteína morfogenética de hueso humano recombinante 2 ... | ||||||||||||||||||
Medical condition: Sujetos con disminución de la densidad mineral ósea (DMO) en riesgo de fractura de cadera | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Female | |||||||||||||||||
Trial protocol: ES (Completed) BE (Completed) PL (Completed) FI (Prematurely Ended) NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004972-74 | Sponsor Protocol Number: 20160227 | Start Date*: 2020-09-15 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta | |||||||||||||
Medical condition: Osteogenesis imperfecta (OI) is a group of genetic skeletal disorders characterized by increased bone fragility, low bone mass , and increased bone turnover contributing to osteoporosis, fracture... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) GR (Completed) IT (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002948-24 | Sponsor Protocol Number: 20080289 | Start Date*: 2013-04-08 | |||||||||||
Sponsor Name:Amgen, Inc. | |||||||||||||
Full Title: An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment with AMG 785 in Postmenopausal Women with Osteoporosis Previously Treated with Bisphosphonate Therapy | |||||||||||||
Medical condition: Post Menopausal Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) DK (Completed) ES (Completed) GB (Completed) CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004913-93 | Sponsor Protocol Number: D1690C00012 | Start Date*: 2009-01-23 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A 24-week, Multi-centre, International, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study with a 78-week Extension Period to Evaluate the Effect of Dapagliflozin in Comb... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SE (Completed) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002487-41 | Sponsor Protocol Number: GLY-321-2017 | Start Date*: 2018-01-31 | |||||||||||
Sponsor Name:GLyPharma Therapeutic Inc. (a wholly owned subsidiary of VectivBio Holding AG) | |||||||||||||
Full Title: A Phase Ib/IIa open-label, repeated dose, metabolic balance study of FE 203799 in patients with short bowel syndrome | |||||||||||||
Medical condition: Short bowel syndrome (SBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004384-31 | Sponsor Protocol Number: SAG/0211PFC-11S1 | Start Date*: 2015-06-10 | |||||||||||
Sponsor Name:Sucampo AG | |||||||||||||
Full Title: A Multicentre, Long-term Safety, Efficacy and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥6 to <18 years with Functional Constipation | |||||||||||||
Medical condition: functional constipation in paediatric patients | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Ongoing) NL (Completed) FR (Ongoing) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004729-42 | Sponsor Protocol Number: 22102014 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:Odense University Hospital, department M [...] | |||||||||||||
Full Title: The effect of testosterone replacement in patients with hypogonadotroph hypogonadism due to opioid treatment for non-malignant disease A double-blinded, randomized and placebo-controlled trial | |||||||||||||
Medical condition: Male Hypogonadism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001552-19 | Sponsor Protocol Number: TOPMATEPY4067 | Start Date*: 2014-12-16 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as Monotherapy in Pediatric Subjects ... | |||||||||||||
Medical condition: New-onset or recent-onset epilepsy. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) IT (Completed) HU (Completed) BE (Completed) DE (Completed) GB (Completed) FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006184-19 | Sponsor Protocol Number: SPI-62-CL-2001 | Start Date*: 2022-06-22 | |||||||||||
Sponsor Name:Sparrow Pharmaceuticals, Inc. | |||||||||||||
Full Title: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome | |||||||||||||
Medical condition: Cushing’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000331-63 | Sponsor Protocol Number: HGB-210 | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name: bluebird bio, Inc. | |||||||||||||
Full Title: A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease. | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
